Mapp Biopharmaceutical, INC.
UEI M9V9QTHR1H28 · CA · SAM.gov record ↗
$48.1M
FY2025 obligations
10
Contract awards
Jun 27, 2016
First action
Sep 16, 2025
Latest action
Obligations by agency
- Department Of Health And Human Services$47.9M
- Department Of Defense$171K
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Contracts ending within 18 months (recompete watch)
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| HHSO100201600021C ↗ | SUPPORT THE INITIATION, MAINTENANCE, AND EXECUTION OF A ZMAPP EAP IN THE US AND AFRICA, INCLUDING CLINICAL, QUALITY, REGULATORY, AND OPERATIONAL SUPPORT AS WELL AS THE EARLY CLINICAL STUDIES (PHASE 1) REQUIRED TO ENABLE FIELD USE OF MBP091 AND MBP134 | Office Of Assistant Secretary For Preparedness And Response | 541720 | $-2.1M | Jun 27, 2016 | Dec 31, 2027 |
Largest awards
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50122C00061 ↗ | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE RATE LETTER MOD | Office Of Assistant Secretary For Preparedness And Response | 541714 | $49.9M | Sep 30, 2022 | Sep 30, 2031 |
| HT942525F0237 ↗ | ANTIBODY & ANTIGEN SUPPLY | Defense Health Agency | 325413 | $111K | Jun 6, 2025 | Dec 4, 2025 |
| HT942525FE048 ↗ | HUMAN-DERIVED MONOCLONAL ANTIBODIES AND RECOMBINANT ANTIGENS | Defense Health Agency | 325413 | $61K | Sep 19, 2025 | Feb 25, 2026 |
| 75A50124C00003 ↗ | NO COST MODIFICATION TO TRANSFER GOVERNMENT FURNISHED PROPERTY UNDER BARDA CONTRACT NO. 75A50122C00076 TO BARDA CONTRACT NO. 75A50124C00003. | Office Of Assistant Secretary For Preparedness And Response | 541714 | $43K | Mar 20, 2024 | Dec 31, 2032 |
| HT942525D0009 ↗ | MATERIAL REQUIREMENT FOR THE DELIVERY OF ANTIBODY AND ANTIGEN SUPPLY. | Defense Health Agency | 325413 | $0 | Jun 1, 2025 | — |
| 75A50122C00076 ↗ | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. | Office Of Assistant Secretary For Preparedness And Response | 541714 | $0 | Sep 28, 2022 | May 1, 2031 |
| 75A50118C00024 ↗ | ADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTERMEASURE TO TREAT ACTIVE INFECTIONS OF SUDAN VIRUS - UPDATE INDIRECT RATES LETTER | Office Of Assistant Secretary For Preparedness And Response | 541715 | $0 | Sep 25, 2018 | Dec 31, 2024 |
| 75A50119D00018 ↗ | NO COST MODIFICATION TO CHANGE PRIMARY AND SECONDARY COR. | Office Of Assistant Secretary For Preparedness And Response | 541714 | $0 | Jun 3, 2019 | — |
| 75A50120C00198 ↗ | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0001 TO ALIGN WITH IPP. | Office Of Assistant Secretary For Preparedness And Response | 541714 | $0 | Sep 30, 2020 | Jun 30, 2026 |
| HHSO100201600021C ↗ | SUPPORT THE INITIATION, MAINTENANCE, AND EXECUTION OF A ZMAPP EAP IN THE US AND AFRICA, INCLUDING CLINICAL, QUALITY, REGULATORY, AND OPERATIONAL SUPPORT AS WELL AS THE EARLY CLINICAL STUDIES (PHASE 1) REQUIRED TO ENABLE FIELD USE OF MBP091 AND MBP134 | Office Of Assistant Secretary For Preparedness And Response | 541720 | $-2.1M | Jun 27, 2016 | Dec 31, 2027 |